medigraphic.com
ISSN 1684-1824 (Electronic)

2012, Number 1

<< Back Next >>

Rev Méd Electrón 2012; 34 (1)

Clinical, anthropometric and laboratory characterization of women with type 2 diabetes mellitus

Mariño SAL, Miguel SPE, Ochoa RM, Cruz FJD, Cruz BY, Rivas EM

Language: Spanish
References: 27
Page:
PDF size: 100.32 Kb.


ABSTRACT

Introduction: The diabetes mellitus is a public health problem and its understanding would help to reduce complications.
Objective: Characterizing the patients with type 2 diabetes mellitus based on clinical, anthropometric, and laboratory variables.
Methods: Cross-sectional study in the municipality of Holguin to a prospective sample per groups of 134 women with risk factors. We applied the ANOVA, the Mann-Whitney test and X2 with α = 0,05, in SPSS.
Results: The diabetes mellitus frequency was 43,2 %. Diabetic women had higher values of age, waist circumference, waist/hip ratio, blood pressure, blood glucose and triglycerides than patients without diabetes mellitus (n = 74); the opposite occurred with the hip circumference. It was found a significant association between the diabetes mellitus and the presence of the metabolic syndrome ( X2 = 41,570; p = 0,000). The diabetes was associated with the body weight excess ( X2 = 7,506; p = 0,023), the ischemic heart disease ( X2 = 6,778; p = 0,009), and the arterial hypertension ( X2 = 5,245, p = 0,022), although it was not associated with smoking ( X2 = 0,233, p = 0,629).
Conclusions: It is important the characterization of the diabetes mellitus because of the high frequency of co-morbidities such as the metabolic syndrome, the ischemic heart disease, the arterial hypertension, the obesity, the atherogenic dyslipidemia. We recommend the intervention of these patients with changes in their lifestyle, incorporating new variables and extending the research to the province of Holguin.


REFERENCES

  1. González Suárez RM, Perich Amador P, Arranz Calzado C. Trastornos metabólicos asociados con la evolución hacia la diabetes mellitus tipo 2 en una población en riesgo. Rev Cubana Endocrinol [Internet]. 2010 [citada 5 Sep 2011];21(2): [aprox. 16 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_issuetoc&pid=1561-295320100002&lng=es&nrm=iso.

  2. Calderín Bouza RO, Prieto Valdés M, Cabrera Rode E. Síndrome de insulinorresistencia en niños y adolescentes. Rev Cubana Endocrinol [ Internet]. 2007 [citado 10 Feb 2011];18(2):[aprox. 15 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_issuetoc&pid=1561-295320070002&lng=es&nrm=iso

  3. Rodríguez Porto AL, Sánchez León M, Martínez Valdés LL. Síndrome metabólico. Rev Cubana Endocrinol [Internet]. 2002 [citada 10 Mar 2011];13(3):[aprox. 15 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_issuetoc&pid=1561-295320020003&lng=es&nrm=iso.

  4. Miguel Soca PE. Evaluación de la resistencia a la insulina. Aten Primaria. 2010;42(9):489-90.

  5. Ministerio de Salud Pública. Anuario estadístico. La Habana: Ministerio de Salud Pública de Cuba; 2006. p. 25-6.

  6. Lwanga SK, Lemeshow S. Simple size determination in health studies: a practical manual. Geneva: World Health Organization; 1991. p. 23-33.

  7. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(Suppl 1):S12-54.

  8. Boinpally T, Jovanovic L. Management of Type 2 Diabetes and Gestational Diabetes in Pregnancy. Mt Sinai J Med. 2009; 76:269-80.

  9. Comisión Nacional Técnica Asesora del Programa de Hipertensión Arterial. MINSAP. Cuba. Hipertensión arterial. Guía para la prevención, diagnóstico y tratamiento. La Habana: Editorial Ciencias Médicas; 2008.

  10. Keck FS, Duntas LH. Brunner's missing experience delayed progress in diabetes research by 200 years. Hormones (Athens). 2007;6:251-4.

  11. Alegría Ezquerra E, Castellano Vázquez JM, Alegría Barrero A. Obesidad, síndrome metabólico y diabetes. Rev Esp Cardiol. 2008;61(7):752-64.

  12. Samuels TA, Cohen D, Brancati FL, Coresh J, Kao WHL. Delayed diagnosis of incident Type 2 Diabetes Mellitus in the ARIC Study. Am J Manag Care. 2006; 12:717-24.

  13. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5:295-309.

  14. Miguel Soca PE, Niño Peña A. Consecuencias de la obesidad. ACIMED [Internet]. 2009 [citado 5 Abril 2011]; 20(4):[aprox. 9 p.]. Disponible en: http://www.cocmed.sld.cu/no84/n84ori5.htm.

  15. Castellanos González MF, Benet Rodríguez M, Morejón Giraldoni AF, Colls Cañizares Y. Obesidad abdominal, parámetro antropométrico predictivo de alteraciones del metabolismo. Revista Finlay [Internet]. 2011 [citado 10 Sep 2011];1(2):[aprox. 8 p.]. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/issue/view/7/showToc.

  16. Fuster V, Ibáñez B. Diabetes y enfermedad cardiovascular. Rev Esp Cardiol. 2008; 8:35-44.

  17. Ferns G, Keti V. HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem. 2008;45:122-8.

  18. Holvoet P; De Keyzer D, Jacobs DR. Oxidized LDL and the Metabolic Syndrome. Future Lipidol. 2008; 6(3):637-49.

  19. Ginsberg HN, MacCallum RP. The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. J Clin Hypertens. 2009;11(9):520–7.

  20. Gimeno Orna JA, Boned Juliani B, Lou Arnal LM. Prevalencia de síndrome metabólico en pacientes con diabetes tipo 2. An Med Interna. 2007;21(6):59-61.

  21. Licea M, Singh O, Smith A, Martínez R. Frecuencia, características clínicas y resultados terapéuticos de la hipertensión arterial en diabéticos tipo 2 en un área de salud. Rev Cubana Endocrinol [Internet]. 2002 [citada 11 Sep 2011];13(2):[aprox. 10 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532002000300008&lng=es&nrm=iso&tlng=es

  22. Crespo Mojena N, Martínez Hernández A, Rosales González E, Crespo Valdés N, Roura García J. Diabetes mellitus e hipertensión. Estudio en el nivel primario de salud. Rev Cubana Med Gen Integr [Internet]. 2002 [citada 2 Ene 2011];18(5):[aprox. 7 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_issuetoc&pid=0864-212520020005&lng=es&nrm=iso.

  23. Swei A, Lacy F, Delano FA, Schmid-Schonbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension. 1997;30:1628-33.

  24. Clavijo, Z. Aspectos relativos a la relación existente entre la obesidad y la hipertensión. Int J Med Sci Phys Educ Sport. 2009;5(1):49-58.

  25. Francischetti EA, Celoria BMJ, Francischetti A, Genelhu VA. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Rev Cardiovasc Ther. 2008;6(3):289–303.

  26. Kuh D, Langenberg C, Hardy R, Kok H, Cooper R. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British Birth Cohort Study. BJOG. 2005;112(4):476-85.

  27. Nishiyama M, Muto T, Minakawa T, Shibata T. The combined unhealthy behaviors of breakfast skipping and smoking are associated with the prevalence of diabetes mellitus. Tokuyu J Exp Med. 2009:259-64.




2020     |     www.medigraphic.com